MedImmune has signed an agreement with Human Genome Sciences to lease a portion of the HGS headquarters facility in Rockville, MD, for the development and manufacturing of clinical trial material for cell culture-based seasonal and pandemic influenza vaccine. The expanded capability will support MedImmune’s commitment to pandemic influenza vaccine development per a five- year, approximately $170 million contract awarded last year by the U.S. Department of Health and Human Services (HHS). F...